Meta AnalysisID 1420
治疗前De Ritis比值（天冬氨酸转氨酶/丙氨酸转氨酶比值）在泌尿系统癌症中的预后作用：一项系统评价与Meta分析
CRD42019142310
What is the prognostic value of the pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) in patients with urological cancers?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1420
- Evidence Id
- 9978
- Core Evidence Id
- 9978
- Source Meta Analysis Id
- 1375
- Herb2 Meta Analysis Id
- HBMA001375
- Crd Id
- CRD42019142310
- Title
- Prognostic role of pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) in urological cancers: a systematic review and meta-analysis
- Review Question
- What is the prognostic value of the pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) in patients with urological cancers?
- Study Type Included
- Inclusion criteria: 1. Studies in which the prognostic role of the AST/ALT ratio for patients with urological cancers has been investigated; 2. Observational studies; 3. Studies involving patients with a histopathologically-confirmed diagnosis of upper tract urothelial cancer (UTUC), renal cell carcinoma (RCC), prostate cancer (PCa), bladder cancer (BCa); 4. Studies involving patients in whom the dNLR has been calculated from blood samples before treatment; 5. Studies reported the association of pretreatment AST/ALT ratio with specific endpoints, including overall survival (OS), cancer-specific survival (CSS), progression-free survival (DFS), and biochemical recurrence-free survival (BRFS); 6. Studies directly provided hazard ratios (HRs) and 95% confidence interval (CI). Exclusion criteria: 1. Studies didn’t provide critical data, such as HRs and 95% CIs for study endpoints; 2. Studies about basic research; 3. Letters, abstracts, opinions, reviews, and case report; 4. Studies didn’t analyze AST/ALT ratio as dichotomous variable, or didn’t clearly reported the cut-off value; 5. Duplicated studies based on the same cohort.
- Condition Being Studied
- Urological cancer; aspartate transaminase; alanine transaminase; prognosis; meta-analysis
- Participant
- Inclusion: patients were histopathologically diagnosed with urological cancers, including upper tract urothelial cancer (UTUC), renal cell carcinoma (RCC), prostate cancer (PCa), bladder cancer (BCa), in whom the AST/ALT ratio has been calculated from blood samples before treatment. Exclusion: animal studies.
- Animal
- Human Disease Modelled
- Intervention
- High pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) of peripheral blood.
- Comparator Control
- Low pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) of peripheral blood.
- Main Outcome
- Overall survival. Measures of effect Hazard ratio and 95% confidence interval.
- Outcome Measure
- Additional Outcome
- Cancer-specific survival, progression-free survival, and biochemical recurrence-free survival. Measures of effect Hazard ratio and 95% confidence interval.
- Study Method
- Diagnostic, Meta-analysis, Prognostic, Systematic review
- Keyword
- Alanine Transaminase; Aspartate Aminotransferases; Humans; Prognosis; Urologic Neoplasms
- Contact
- Chao Li [email protected]
- Organisational Affiliation
- The First Hospital of Shijiazhuang
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-07-13
- Registration Date
- 2019-10-07
- Anticipated Start Date
- 2019-06-12
- Anticipated Completion Date
- 2019-08-15
- Title Cn
- 治疗前De Ritis比值（天冬氨酸转氨酶/丙氨酸转氨酶比值）在泌尿系统癌症中的预后作用：一项系统评价与Meta分析
- Title En
- Prognostic role of pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) in urological cancers: a systematic review and meta-analysis
- Bilingual Status
- complete